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Abstract
Background: Plasmacytoid Dendritic Cells (pDC) comprise approximately 0.2 to 0.8% of the
blood mononuclear cells and are the primary type 1 interferon (IFN), producing cells, secreting high
levels of IFN in response to viral infections. Plasmacytoid dendritic cells express predominantly
TLRs 7 & 9, making them responsive to ssRNA and CpG DNA. The objective of this study was to
evaluate the molecular and cellular processes altered upon stimulation of pDC with synthetic TLR
7 and TLR 7/8 agonists. To this end, we evaluated changes in global gene expression upon
stimulation of 99.9% pure human pDC with the TLR7 selective agonists 3M-852A, and the TLR7/8
agonist 3M-011.
Results: Global gene expression was evaluated using the Affymetrix U133A GeneChip® and
selected genes were confirmed using real time TaqMan® RTPCR. The gene expression profiles of
the two agonists were similar indicating that changes in gene expression were solely due to
stimulation through TLR7. Type 1 interferons were among the highest induced genes and included
IFNB and multiple IFNα subtypes, IFNα2, α5, α6, α8, α1/13, α10, α14, α16, α17, α21. A large
number of chemokines and co-stimulatory molecules as well as the chemokine receptor CCR7
were increased in expression indicating maturation and change in the migratory ability of pDC.
Induction of an antiviral state was shown by the expression of several IFN-inducible genes with
known anti-viral activity. Further analysis of the data using the pathway analysis tool MetaCore gave
insight into molecular and cellular processes impacted. The analysis revealed transcription
networks that show increased expression of signaling components in TLR7 and TLR3 pathways,
and the cytosolic anti-viral pathway regulated by RIG1 and MDA5, suggestive of optimization of an
antiviral state targeted towards RNA viruses. The analysis also revealed increased expression of a
network of genes important for protein ISGylation as well as an anti-apoptotic and pro-survival
gene expression program.
Conclusion: Thus this study demonstrates that as early as 4 hr post stimulation, synthetic TLR7
agonists induce a complex transcription network responsible for activating pDC for innate anti-
viral immune responses with optimized responses towards RNA viruses, increased co-stimulatory
capacity, and increased survival.
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Background
Dendritic cells constitute a heterogeneous population of
antigen presenting cells that are critical for bridging the
innate and the adaptive immune responses [1-3]. In the
blood, DC can be sub-divided into two major popula-
tions, CD11c+ and CD11c-. The CD11c+ population is
thought to be myeloid derived, therefore called myeloid
or conventional DC (cDC). The CD11c- population, also
known as plasmacytoid dendritic cells (pDC) appears to
be lymphoid-derived and constitutes a population of cells
that can migrate from the blood directly to lymphoid tis-
sues [4]. pDC comprise approximately 0.2 to 0.8% of the
blood mononuclear cells and are the primary type 1 inter-
feron (IFN), producing cells, secreting high levels of these
cytokines in response to viral infections [5] and stimula-
tion with TLR7 and TLR9 agonists [6,7]. Type I IFNs are
clinically important cytokines and are used for anti-viral
[8] and anti-cancer therapy [9]. In addition to their direct
anti-viral and anti-proliferative affects, type I interferons
are important in bridging the innate and adaptive
immune responses. Type 1 interferons have been shown
to increase the expression of MHC class I and II, enhance
co-stimulatory marker expression on DC, modulate
immunoglobulin production, synergize with IL-12 to
enhance IFN-γ production, and augmente NK and CTL
responses [2,5,3].
pDC express a limited repertoire of toll like receptors
(TLR), expressing predominantly TLR7 and TLR9 [10] and
can be stimulated to produce large amounts of type 1 IFN
in response to the natural TLR7 and TLR9 agonists guano-
sine- and uridine-rich ssRNA and DNA containing CpG
motifs respectively [11,12]. Synthetic imidazoquinoline-
like molecules exemplified by imiquimod (R-837) and
resiquimod (R-848) have been identified as TLR7 agonists
based on their inability to induce the cytokines TNFα, IL-
12, or IFNα in TLR7-deficient mice [13]. In HEK293 cells
transfected with TLR7 or TLR8, imiquimod and 3M-852A
have been shown to posses a much higher potency at acti-
vating NFκB through TLR7 compared to TLR8, thus show-
ing selectivity for TLR7 [14,15]. Resiquimod on the other
hand activated NFκB through TLR7 and TLR8 at compara-
ble levels [14] as did 3M-011 [16]. The TLR7 agonists imi-
quimod, and 3M-852A were found to activate pDC for the
production of IFNα while the TLR8 agonist 3M-002 acti-
vated cDC for the production of IL12, and the TLR7/8 ago-
nist resiquimod activated both cDC and pDC for cytokine
production [14]. Thus, the TLR7 agonist 3M-852A is an
ideal tool to study the molecular processes impacted
through TLR7 in pDC.
The TLR7 agonist imiquimod is used for the treatment of
various virally induced diseases such as genital warts [17]
and for the treatment of cancerous and pre-cancerous skin
lesions such as basal cell carcinoma (BCC) [18] and
actinic keratosis (AK) [19]. The anti-viral and anti-tumor
activity of synthetic TLR7 agonists has been attributed to
the induction of cytokines such as IFNα [20,21]. Gene
expression analysis of skin biopsies of patients with AK
and BCC after topical treatment with imiquimod has
shown that the TLR7 agonist induces the expression of a
large number of interferon inducible genes indicating the
importance of type 1 interferons in the mechanism of res-
olution of pre cancerous and cancerous skin lesions [22-
24]. The TLR7 agonist 3M-852A is currently in phase II
clinical trials for the therapy of cancer.
To date, the molecular pathways and processes of TLR7-
mediated activation of pDC, the primary target of TLR7
agonists have not been thoroughly characterized. There-
fore, the objective of this study was to evaluate the molec-
ular and cellular pathways and processes impacted by
stimulation of pDC with TLR7 agonists using global gene
expression analysis in highly pure preparations of pDC.
To this end, we evaluated global gene expression changes
after stimulation of human pDC of greater than 99%
purity with the TLR7 agonist 3M-852A, and the TLR7/8
agonist 3M-011 using Affymetrix U133A GeneChips. Fur-
ther analysis of the data in the context of Gene Ontology
classification and gene regulatory network analysis ena-
bled us to identify molecular and cellular pathways
impacted by stimulation of pDC through TLR7.
Results and discussion
Characterization of pDC Purity
Even though pDC are reported to express high levels of
TLR7, other cells in PBMCs, such as monocytes also
express TLR7 [10] and can contribute to TLR7-mediated
events. Therefore, in order to determine TLR7-mediated
gene expression specific to pDC, high purity pDC prepa-
rations are necessary. Positive cell selection using BDCA4
antibody resulted in pDC enriched preparations with var-
iable purity ranging from 40% to 80%. Further purifica-
tion using flow cytometry after staining cells with APC-
labeled anti-CD123 antibody and FITC-labeled BDCA2
antibody resulted in pDC preparations that were greater
than 99% pure. Figure 1A and 1B show representative his-
tograms from flow cytometer analysis of pDC-enriched
(67%) preparation (Figure 1A) and a 99% pure pDC prep-
aration (Figure 1B) after flow purification, as evaluated by
the percentage of CD123+, BDCA2+, CD11c- cells.
Purity of pDC preparations were also followed by moni-
toring the expression of various TLRs using real time
RTPCR. Figure 2A and 2B show the expression of various
TLRs in preparations of varying pDC purity. Figure 2A
shows that as the purity of the pDC preparation increased,
the expression of TLR4, TLR5 and TLR8 decreased. Con-
versely, the expression of TLR7, TLR9, and TLR10
increased up to a purity of 82% then decreased somewhatBMC Immunology 2007, 8:26 http://www.biomedcentral.com/1471-2172/8/26
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(Figure 2B), potentially indicating loss of a cell type which
may be enriched in expression of these TLRs. Alternatively
the variability in the expression of these TLRs for prepara-
tion > 82% pDC purity may be explained by donor-to-
donor variability in expression. The expression of TLR1
and TLR6 remained somewhat constant.
Induction of Type 1 Interferons genes: confirmation by real 
time RTPCR
GO molecular function analysis of Affymetrix GeneChip
data showed that 14 out of 68 genes classified as hemato-
poeitin/interferon-class (D200-domain) cytokines, and
10 type-1 IFN genes were increased in expression by the
TLR7 agonists. In addition, these genes were the highest
induced genes in the data set with a median Log2 fold
change in expression (across compounds and donors)
ranging from 2.6 to 13. The interferon genes shown to be
consistently induced in all donors were IFNA1, IFNA2,
IFNA4, IFNA5, IFNA7, IFNA10, IFNA13, IFNA14,
IFNA16, IFNA17, IFNA21, IFNB1, and IFNW1. IFNA6 and
IFNA8 expression was donor variable, IFNA6 expression
was detected in 3 of 4 donors for 3M-852A and 1 of 2
Increasing purity of pDC preparations correlate with  decrease in the expression of TLR4, TLR5, and TLR8 Figure 2
Increasing purity of pDC preparations correlate with 
decrease in the expression of TLR4, TLR5, and TLR8. 
(A) Change in expression of TLR4 (circles), TLR5 (squares), 
and TLR8 (triangles), and (B) TLR1 (diamonds), TLR6 
(squares), TLR7 (triangles), TLR9 (circles), and TLR10 (stars) 
with increasing purity of pDC preparation. TLR expression 
was determined by real time RTPCR analysis. Relative copy 
number was calculated with respect to 2 ng cDNA after nor-
malization to expression levels of GAPDH in each sample.
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Purity of pDC preparations as determined by flow cytometry Figure 1
Purity of pDC preparations as determined by flow 
cytometry. Representative histograms for partially purified 
pDC (A) and flow purified pDC (B). pDC were separated 
from PBMC using anti BDCA4 microbeads. The partially 
purified cells were then labeled with CD123-APC, BDCA2-
FITC, and CD11c-PE antibodies and sorted on a FACSAria 
flow cytometer to a final purity of > 99%. Numbers in the 
top, left hand corner of the dot plots indicate the percentage 
of CD123+, BDCA-2+, CD11c- cells.
67% 67%
A
99% 99%
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donors for 3M-011. IFNA8 expression was detected in 2 of
4 donors for 3M-852A and, 1 of 2 donors for 3M-011.
In order to confirm the induction of the interferon genes,
we performed real time RTPCR. Analysis of the time
dependence of induction of type 1 interferons by 3M-
852A from 1 donor using real time RTPCR (data not
shown) showed that induction of IFNB, IFNA2, IFNA8
and IFNA14 was high (log2 fold change = 6.6) at 30 min-
utes post stimulation and reached peak levels at 1.5 hr
(log2 fold change ~12), and remained at high levels 4 hr
post stimulation. Induction of IFNA5, IFNA6, IFNA10,
IFNA13, and IFNA21 were relatively low (log2 fold
change of 2 to 5) 30 minutes post stimulation and peak
levels were achieved 4 hrs post stimulation. Table 1 shows
a comparison of expression data obtained by Affymetrix
analysis and real time RTPCR analysis at 4 hr post stimu-
lation for the interferon genes as well as for other selected
genes. Specific primers and probes for RTPCR were not
available for four of the interferon alpha subtypes (IFNA4,
IFNA7, IFNA16, and IFNA17) at the time of data collec-
tion. The reagents for IFNA1 in the RTPCR study detected
both IFNA1 and IFNA13. Of the interferon genes tested by
both Affymetrix and real Time RTPCR, all IFNA subtypes
and IFNB showed increased expression by both methods
indicating good concordance.
In humans, the type 1 interferon family of genes consists
of 13 IFNA subtypes, IFNB, IFNW, IFNE1 also know as
IFN-tau1, and IFNK [25]. pDC are known to produce high
levels of type 1 interferons in response to viruses [1,26,27]
and various toll like-receptor ligands including TLR7[14]
and TLR9 [28]. We show that stimulation of pDC through
TLR7 results in the induction of IFNB and the majority (if
not all) IFNA subtypes induced by viruses such as herpes
simplex virus type 1(HSV-1) and Sendai virus (SV) [26]
and H3N2 flu virus [27]. Since the anti-viral and anti-
tumor activities of the different IFNA subtypes have been
shown to differ [29-31] induction of a variety of IFNA sub-
types by TLR7 agonists may be an advantage for anti-viral
and anti-tumor therapy.
TLR7-mediated cytokine protein expression
In order to confirm the expression of some of the genes at
the protein level, ELISA and Luminex multiplex protein
assays were used to determine the expression of several
secreted cytokines and chemokines. Supernatants were
collected after stimulation of pDC for 4 hr. Of the 25
cytokines and chemokines tested, IFNα, TNFα, IL8, IL6,
MIP-1α (CCL3), and MIP-1β (CCL4) proteins were
induced at high levels > 1000 pg/ml. This is consistent
with the high level of expression of these genes observed
by Affymetrix and real time RTPCR analysis (Table 1). Fig-
ure 3A shows the induction of these cytokines for 3M-
852A and 3M-011. In contrast, low levels of IL-1β,
IL12p70, GM-CSF, Rantes (CCL5), MCP-1 (CCL2), and
IP10 (CXCL10) proteins were detected (Figure 3B). The
genes for IL1β, IL12, GM-CSF, and MCP1 (CCL2) were
not increased in expression in the Affymetrix or real time
RTPCR data. In contrast, high levels of gene expression
(up to a fold change of 900) were observed for CXCL10
and CCL5. The seeming disparity may be due to the fact
that data was collected at 4 hr post stimulation and the
proteins for these genes may not have reached peak
expression. Consistent with the gene expression data, the
proteins IL-1RA, IL-2, IL-4, IL-5, IL-7, IL-10, IL-13, IL-15,
IL17, IFNγ, MIG (CXCL9), and Eotaxin (CCL11) were not
induced by TLR7 agonists in pDC 4 hr post stimulation.
However, induction of these genes and proteins at a differ-
ent time than 4 hr post stimulation can not be ruled out.
Table 1: Comparison of gene expression changes as determined 
by Affymetrix GeneChip analysis and real time RTPCR
Gene 
Symbol
Log2 Fold 
Change: Affymetrix
Log2 Fold 
Change: Real Time RTPCR
3M-852A 3M-011 3M-852A 3M-011
IFNA1 7.2 10.2 8.9 8.0
IFNA10 5.4 6.7 7.5 7.0
IFNA13 5.5 6.6 NA NA
IFNA14 6.7 7.9 10.2 8.2
IFNA16 6.0 5.0 NA NA
IFNA17 5.1 4.3 NA NA
IFNA2 6.8 6.0 11.0 9.3
IFNA21 7.7 6.7 9.2 8.0
IFNA4 5.9 5.1 NA NA
IFNA5 6.3 5.8 9.8 8.6
IFNA6 2.6 1.3 5.0 3.7
IFNA7 5.9 4.9 NA NA
IFNA8 2.8 2.7 8.0 7.2
IFNB1 8.0 6.2 10.4 8.6
Bcl-2 1.4 1.2 3.1 2.7
BCL2L1 4.2 3.8 5.1 5.0
CCL3 2.6 1.2 3.2 0.9
CD80 2.5 1.8 5.6 4.9
CXCL10 5.2 5.7 7.5 8.3
GIP2 2.8 3.2 2.0 4.0
MX1 1.4 1.6 2.3 2.4
MYC 4.6 2.2 7.1 5.9
MYD88 1.3 1.6 2.1 2.3
PTGS2 3.5 1.2 5.4 3.1
STAT1 1.0 1.2 1.3 1.1
TNF 2.4 1.4 3.2 2.2
1Taqman primers and probes for IFNA1 in the real time RTPCR 
detect both FINA1 and IFNA13. Fold change in expression were 
calculated with respect to un-stimulated pDC. For the Affymetrix 
data, values are averages of data sets for four donors for 3M-852A 
and two donors for 3M-011. For the real time RTPCR data, values 
are averages of two data sets from two donors for each compound. 
NA designates not analyzed.BMC Immunology 2007, 8:26 http://www.biomedcentral.com/1471-2172/8/26
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GO classification of Affymetrix GeneChip data
In order to determine TLR7-mediated global gene expres-
sion changes, Affymetrix GeneChip analysis was per-
formed after stimulation of pDC with TLR7 selective
agonists 3M-852A, and the TLR7/8 agonist 3M-011. Stim-
ulation of pDC for 4 hours resulted in changes in expres-
sion of 680 genes with consistent expression changes
across replicates for at least one of the compounds tested
(see Additional File 1). Out of the 680 genes, 430 genes
were increased in expression and 250 genes were
decreased in expression due to stimulation with at least
one TLR agonist in all donors tested. Figure 4 shows a two
way hierarchical clustering of the 680 genes altered in
expression. Samples clustered primarily according to
donor rather than compound indicating that the com-
pounds exhibit an overall similar gene expression profile,
consistent with gene expression changes regulated
through activation of TLR7. Subtle differences are appar-
ent in the response of the same donor to the different ago-
nists, primarily in the magnitude of change in expression.
In order to explore the biological significance of TLR7-
mediated gene expression changes, we analyzed their
Gene Ontology (GO) classification using MetaCore as
well as the GO browser in Spotfire for Functional Genom-
ics. The most highly represented processes include: pro-
grammed cell death, specifically negative regulation of
programmed cell death and anti-apoptosis, immune
response, response to virus, inflammatory response and
defense response. Analysis for GO function classification
showed that the most highly represented GO function is
cytokine activity, including hematopoeitin/interferon
class (D200 domain) containing proteins and chemok-
ines (p values 10-11 to 10-5). Other functional groups
enriched in the data set include genes with oxidoreductase
activity, protein ubiquitin ligase activity and guanine
nucleotide binding activity. The role of some of these
processes in pDC activation will be discussed below.
Analysis of gene regulatory networks
In order to further understand the molecular processes
initiated following stimulation of pDC with 3M-852A and
3M-011 the expression data were input into MetaCore
and analyzed for protein regulatory networks enriched
with the expression data. The 680 genes altered in expres-
sion were used as a list of input nodes and subjected to the
Analyze Networks (Receptors) algorithm and the Analyze
Networks (Transcription regulation) algorithm (see Meth-
ods for details). These algorithms generate a virtual short-
est paths network between all nodes from the input list
and parse them into sub-networks centered on receptors
and transcription factors respectively. Analysis of the data
using the receptor networks algorithm resulted in 30 sub
networks focused on various receptors leading to activa-
tion of various transcription factors. The top ten signifi-
cant networks were composed of 40 to 107 genes altered
in expression with p value ranging from 6e-66 to 4e-128.
These top ten networks included transcription regulation
initiated through activation of the chemokine receptor
CCR3, insulin receptor, IGF-1 receptor, IFNα/β receptor,
and CD80-CD86/CTLA4 system.
Analysis of the gene expression data in MetaCore using
the transcription regulation algorithm resulted in 84 sub
networks centered on various transcription factors. The
top 10 networks consisted of transcription factors which
directly regulated the expression of 12 to 37 genes, with a
total network size of 50 to 80 genes and p value for signif-
icance of network ranging from 8e-95 to 8e-128. The top ten
networks were for the transcription factors p53, CREB1,
IRF1, RelA (p65), HNF6, IRF2, c-Rel, IRF8, NFkb2, and
NFkb p50/p65. These networks were enriched in genes
with GO ontology classification of regulation of physio-
logical processes and regulation of apoptosis (CREB1,
p53, NFkb, c-Rel) and anti-bacterial/antiviral humoral
responses (IRF1, RelA, HNF6, IRF8, NFkB2, NFkB p50/
Cytokines secreted by flow purified pDC 4 hr post-stimula- tion with TLR7 agonists Figure 3
Cytokines secreted by flow purified pDC 4 hr post-
stimulation with TLR7 agonists. Cell culture superna-
tants collected after stimulation were evaluated for cytokine 
protein expression using a Luminex 25-Plex assay. (A) 
Secreted TNFα, IL8, IFNα, MIP-1α, MIP-1β and IL6. (B) 
secreted IL1β, IL2R, IL12P70, Rantes, GM-CSF, MCP-1, and 
IP-10. Dotted bars, vehicle stimulated samples; hatched bars, 
3M-852A-stimulated samples and solid bars, 3M-011-stimu-
lated samples. The results are expressed as mean + SD, n = 2 
donors.
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Cluster analysis of 680 genes regulated in expression by 3M-852A and 3M-011 Figure 4
Cluster analysis of 680 genes regulated in expression by 3M-852A and 3M-011. Gene expression analysis was per-
formed at 4 hr post-stimulation of flow-purified pDC with 3M-852A and 3M-011 using the Affymetrix GeneChip U133A as 
described in Methods. D1 and D2, designate two different donors for pDC preparation in which the pDC purity was > 99%. 
Global gene expression was determined using the Affymetrix U133A GeneChip. Two-way hierarchical clustering was per-
formed as described in the Methods section, using the Unweighted Pair-Group Method with Arithmetic mean (UPGMA) and 
the Euclidean similarity measure. The log2 fold change values were used for the analysis. Insert bar chart shows the expression 
change scale with red, green, and white signifying increased, decreased, and unchanged expression, respectively. Expression 
changes were evaluated with respect to vehicle stimulated pDC from the same donor. Expression changes for the 680 genes 
are documented in Additional File 1.
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p65). Two other networks centered on IRF7 (p value = 6e-
85) and IRF9 (p value = 1e-81) and were enriched in genes
with GO ontology classification of defense response and
virus response. Some of the interaction networks derived
from the above analysis will be discussed in the following
sections.
Transcription regulatory network indicates utilization of 
various transcription factors following activation of TLR7
Recent research has implicated the involvement of various
transcription factors including NFkB, AP1, IRF7, and IRF5
in signaling through TLR7 [32] in various immune cells as
well as cells transfected with TLR7 [14]. Even though the
direct activation of IRF7 through TLR7 has been demon-
strated in pDC, the direct activation of other transcription
factors has not been documented. Figure 5 shows a tran-
scription network which illustrates interactions between
the TLR7 signaling pathway components and transcrip-
tion factors known to be activated by the TLR7 pathway in
other cell types including IRF7, NFkB, IRF5, and c-Jun.
The network includes protein-protein binding interac-
tions, protein phosphorylation and transcription regula-
tion. Some of the TLR7 signaling components have been
omitted for the sake of clarity. The figure shows genes that
are know to be transcriptionally regulated by IRF7, NFkB,
IRF5, IRF8, c-Jun and through ISGF3 via activation of the
IFNα/β receptor. Exemplified are transcriptional regula-
tion through NFkB, e.g. CCR7, Gro-1 (CXCL1), Gro-
gamma (CXCL3) and CD44; through IRF7: e.g. type 1
interferons and TAP2; through NFkB and IRF5, e.g. IL8
and MIP-1β (CCL4); through NFkB and c-Jun, e.g. TNFA,
MIP-β, Gro-β (CXCL2); through IRF8, H28 and HGK
(MAP4K4); through NFkB, IRF5 and ISGF3, e.g. CCL5;
ISG20 and BCL2.
Interferon regulatory factor 8, IRF8 (also known as
ISCBP8) is a transcription factor recently identified as
being important for the development of type I interferon-
producing cells (pDC) in the mouse [33]. IRF8-/- mice
have also been shown to be unresponsive to CpG in
induction of cytokines, thus indicating the importance of
IRF8 in TLR9 signaling [34]. In addition, interactions
between IRF8 and TRAF6 resulting in enhanced ubiquiti-
nation of TRAF6 has been reported in macrophages [35].
Whereas the role of IRF7 in the signaling ofTLR7 has been
established, the role of IRF8 in signaling of TLR7 has not
been elucidated. Upon stimulation of pDC with 3M-852A
the expression of IRF8 decreased by 2 to 4 fold. The signif-
icance of the decrease is not clear but may be related to
feed-back regulation.
Transcription regulatory network indicates utilization of various transcription factors following activation of TLR7 Figure 5
Transcription regulatory network indicates utilization of various transcription factors following activation of 
TLR7. Protein-interaction network was generated for expression changes in pDC stimulated with 3M-852A and 3M-011 4 hr 
post-stimulation. The network shows genes altered in expression in the data set which were transcriptionally regulated via 
IRF7, NFkB, cJun, IRF5, IRF8 through potential interaction with the TLR7 pathway and through ISGF3 via activation of the type 
1 interferon receptor. Network was generated using the Analyze network (receptor) and the direct interactions algorithms 
using the whole expression data. Major hubs have been highlighted in bold. Remaining details of network are as described in 
Methods. Legend describing symbols in the network is found in Additional file 2.BMC Immunology 2007, 8:26 http://www.biomedcentral.com/1471-2172/8/26
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Interaction of the type 1 interferons with the interferon
receptor results in activation of the JAK-STAT pathway cul-
minating in the translocation of transcriptional complex
ISGF3 composed of STAT1, STAT2 and IRF9 (ISGF3) or
STAT1 dimers (AAF, IFN-a activated factor) to the nucleus
[36]. The complexes bind to specific DNA sequences
called IFN-α stimulated response elements (ISRE) found
in the promoter regions of target genes resulting in
increased expression of several hundred genes. All three
components of the ISGF3 complex, IRF9, STAT1 and
STAT2 were increased in expression upon stimulation of
pDC with TLR7 agonists.
A large number of genes transcriptionally regulated
through ISGF3 are increased in expression (see Additional
File 1). A small number of these genes are shown in the
interaction network of Figure 5, including, MXA, OAS1,
TNFSF10, IFI44, ISG56 and NMI. Many of the genes that
are inducible by type 1 interferons can also be transcrip-
tionally regulated directly via other transcription factors.
For example, the expression of CD86, MIG (CXCL9), IP10
(CXCL10) and CCL5 is known to be directly regulated via
NFkB and IRF5 [37-40] as well as indirectly through type
1 interferons.
Thus, the data demonstrate the complex network of tran-
scriptional regulation initiated through activation of pDC
through TLR7. Direct TLR7-initiated transcription regula-
tion through IRF7, has been documented in pDC [41].
The dependence of TLR9-mediated IL6 induction and
pDC survival on NFKB1 and c-Rel has also been docu-
mented [42]. TLR7-mediated transcription regulation via
IRF5, NFkB and AP1 has not been demonstrated in pDC
but is well documented in other immune cells. Further
study is required to demonstrate the direct utilization of
these transcription factors in TLR7 mediated activation of
pDC.
In addition to the genes regulated by the transcription fac-
tors illustrated in Figure 5, analysis in MetaCore showed
that a large number of genes that are increased in expres-
sion are known to be regulated by the transcription factors
CREB1, c-Myc and p53. Four hr. post-stimulation with
TLR7 agonists, one would expect transcriptional regula-
tion through other secondary pathways activated by the
genes induced in the primary TLR7-mediated pathways.
In addition to type 1 interferons, a large number of other
cytokine and chemokine genes were increased in expres-
sion including the chemokines, CCL5, IL6, IL8, MIP1A,
MIP1B, and the cytokines TNFA and TNFB. In fact, at 4 hr
post-stimulation, significant amounts the proteins for IL6,
IL8, TNFα, MIP-1α and, MIP-1β were produced. These
cytokines can act in an autocrine fashion to activate the
IL8 receptors, CCR1 and CCR3, which are linked to G pro-
teins that can in turn activate various transcription factors.
Figure 6 shows a protein interaction network illustrating
the various chemokines induced in pDC and their respec-
tive G-protein-coupled receptors. Potential activation of
the transcription factors CREB1, c-Myc and NFkB via the
chemokine receptors CCR1, CCR3 and the IL8 receptors is
depicted in Figure 7. Chemokine receptors activate vari-
ous guanine nucleotide proteins (G proteins) including
Stimulation of pDC with 3M-852A and 3M-011 results in increased expression of a large number of chemokines Figure 6
Stimulation of pDC with 3M-852A and 3M-011 results in increased expression of a large number of chemok-
ines. Protein-interaction network was generated for expression changes in pDC 4 hr post stimulation with 3M-852A and 3M-
011. The network was generated using a list of genes in the GO function classification of chemokines and the shortest path 
algorithm. The network summarizes interactions between chemokines increased in expression and their respective receptors. 
Green arrows indicate binding interactions or covalent modifications that result in activation or increased transcription. Red 
arrows indicate binding interactions or covalent modifications that result in inhibition of activity or suppression of transcrip-
tion.BMC Immunology 2007, 8:26 http://www.biomedcentral.com/1471-2172/8/26
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the beta/gamma subunits which result in the activation of
the phospholipase beta (PLCB) and Phosphatidyl inositol
kinase (PI3K) pathways [43,44]. These signaling pathways
culminate in the activation of various transcription factors
including CREB, cMyc, and NFkB. In addition to the
chemokines for these receptors, one of the G-proteins,
GNG11 (guanine nucleotide binding protein gamma 11)
is also increased in expression.
The transcription factors CREB1, c-Myc and NFkB regulate
the transcription of genes important in cell proliferation,
differentiation, and apoptosis. Whereas most of the genes
regulated by NFkB and CREB1 are increased in expression,
a significant percentage of those regulated by c-Myc are
decreased in expression. Several of the down regulated
genes are involved in the regulation of cell cycle and of
apoptosis and include Caspase 8 and BTG2 [45,46].
Genes increased in expression include pro-inflammatory
genes, genes with growth factor activity and or prolifera-
tive activity including GRO1, GROG, GROB, MCL-1
[47,48] and anti-apoptotic activity, BCL2, c-IAP2, CFLIP,
SERPINB9 [49-51]. Thus, the transcription regulatory net-
work shown in Figure 7 suggests that 4 hr post stimulation
with TLR7 agonists, pDC are programmed for cell sur-
vival. This is shown more clearly in Figure 8; a protein reg-
ulatory network built using a list of genes with GO
classification of anti-apoptosis as the input nodes.
Induction of an anti-apoptotic gene expression program
Activation of pDC through TLR7 agonists results in the
induction of TNFR-associated genes that are known to
induce apoptosis. These include TNFA, TNFB and
TNFSF10 (TRAIL). The protein products of these genes
may be expected to induce apoptosis in pDC via autocrine
regulation. However, the gene expression data shows that
TLR7 agonists induce an anti-apoptotic and pro-survival
gene expression program in pDC. Figure 8 depicts a pro-
tein regulatory network for TNFR1, TNFRSF6 (FasR) and
TNFRSF10 (TRAIL receptor)-mediated apoptosis. TNFR
ligands such as TNFA, TRAIL and FAS ligand exert their
apoptotic effect through activation of the caspase cascade
which results in the degradation of several proteins critical
to cell survival pathways [45]. Caspase 8 (CASP8) and
DAPK1 (death-associated protein kinase) genes central to
TNFR1, FasR and TNFRSF10 (TRAIL receptor) mediated
apoptotic death [52] are decreased in expression Concom-
itant with the decreased expression of apoptosis media-
tors, several inhibitors of activation of caspases and
Potential transcription regulation of genes through pathways secondary to stimulation of TLR7 Figure 7
Potential transcription regulation of genes through pathways secondary to stimulation of TLR7. Protein-interac-
tion network was generated for expression changes in pDC stimulated with 3M-852A and 3M-011 4 hr post stimulation. Net-
work was generated using the Analyze network (receptor) and the direct interactions algorithms using the whole expression 
data. The network shows genes altered in expression in the data set that are transcriptionally regulated through NFkB, c-Myc, 
and CREB1. Potential activation of these transcription factors through the chemokine receptor CCR1, CCR3 and the IL8 
receptors is depicted. Bold green lines highlight the canonical pathways for activation of the three transcription factors. Fine 
lines going out of the transcription factors designate transcription regulation. Remaining network details are as described in 
Figure 6.BMC Immunology 2007, 8:26 http://www.biomedcentral.com/1471-2172/8/26
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activators of pro-survival genes are increased in expres-
sion. The anti-apoptotic gene BCL2 which is increased in
expression, inhibits apoptosis mediated by TNFR1 and
caspase 8 [49,53] and is in turn activated by pro-survival
genes such as beta-catenin. The protein products of
CFLAR, c-FLIPS and c-FLIPL inhibit the death receptor
adaptor molecules FADD, DAXX and caspase 10
[50,54,55]. Other anti-apoptotic genes increased in
expression by TLR7 agonists in pDC include the pro-sur-
vival gene MCL-1, which is tightly regulated by pro-apop-
totic genes such as Caspase 3 and Granzyme B [48,56];
SERPINB9 which inhibits Caspase 1 and Granzyme B
[51,57]; cIAP2 (BIRC3, [not shown in figure) which pro-
motes degradation of caspase 3 and caspase 9 through its
ubiquitin ligase activity [58,59]; and BCLXL (BCL2L1)
which inhibits activation of the tumor suppressor protein
p53 [60]. Other pro-survival genes increased in expression
include Pim-2 and TPL2 (not shown in network). Pim-2
(pim-2 oncogene) inhibits the pro-apoptotic protein BAD
(BCL2 antagonist of cell death) [61] and activates the pro-
survival gene TPL2 (MAP3K8) [62]. Figure 8 also shows
that a number of genes that are positively regulated by the
transcription factor p53 are decreased in expression, sug-
gesting that transcription from p53 may be suppressed.
Taken together, the gene expression data suggest that acti-
vation of pDC by TLR7 agonists induces an anti-apoptotic
and pro-survival gene expression program, a state neces-
sary for the migration of pDC to inflammatory sites and
to lymph nodes.
Interferon-inducible genes: Antiviral response
Interferon-inducible genes regulate cellular processes such
as cell growth and differentiation, cell death, and T-cell
costimulation, activation, and migration. Many of these
genes also have direct antiviral activity, including MX1
(MXA) [63] OAS1 [64], PKR (EIF2AK2) [65], ISG15
(G1P2), RSAD2 (Cig5), [66], ISG56 [67], PLSCR1 [68],
IRF1, IRF9, GBP1, IFI-6-16 and IFI27 [69]. Genes such as
IFIH1 and IFI16 have been shown to regulate cell growth
and differentiation [70]. The biological function of other
interferon-inducible genes such as IFIT1, IFIT2, IFIT3,
IFTM1, IFI35, G1P3, and ISG20 are not well understood.
However, these genes have been shown to be part of the
innate anti-viral response [71,72,69]. A comprehensive
discussion of the biological role of IFN-inducible genes is
beyond the scope of this manuscript. The few genes cited
here demonstrate the important role that TLR7 plays in
antiviral, anti-tumor, and immune-regulatory functions
in pDC.
Protein regulatory network indicates importance of 
ISGylation pathway in TLR7-mediated activation of pDC
One of the interferon-inducible genes increased in expres-
sion upon treatment of pDC with TLR7 agonists is ISG15,
interferon stimulated protein 15 (G1P2, UCRP). ISG15
has been shown to function as a cytokine which stimu-
lates IFNγ production as well as proliferation of natural
killer cells and their cytolytic activity [73]. ISG15 contains
two ubiquitin-like domains and is also know to be conju-
Stimulation of pDC with 3M-852A and 3M-011 results in the induction of an anti-apoptotic gene expression program Figure 8
Stimulation of pDC with 3M-852A and 3M-011 results in the induction of an anti-apoptotic gene expression 
program. Protein-interaction network was generated for expression changes in pDC 4 hr post stimulation with 3M-852A and 
3M-011. The network was generated from a list of genes with GO process classification of anti-apoptosis, using the shortest 
path algorithm. The network highlights the large number of anti-apoptotic genes that are increased in expression with a con-
comitant decrease in expression of key pro-apoptotic genes including several that are transscriptionally regulated by p53. 
Remaining network details are as described in Figure 6.BMC Immunology 2007, 8:26 http://www.biomedcentral.com/1471-2172/8/26
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gated to various protein targets [74-76]. The protein
ISGylation pathway uses a similar set of enzymes to that
used by the ubiquitin pathway including the ubiquitin E1
like enzyme UBE1L [77], the ubiquitin E2 enzyme
UBCH8 [78,79] the HECT type ubiquitin E3 ligase HERC5
(also known as ceb1) [80,81] and the ubiquitin E3 liagase
EFP also known as TRIM25 [82].
In this study, evidence for the importance of protein
ISGylation following stimulation of pDC with TLR7 ago-
nists is provided by increased expression of ISG15 and
genes important in the ISGylation pathway. Analysis of
GO process classification showed that 33 genes involved
in the ubiquitin cycle were altered in expression upon
treatment of pDC with 3M-852A and 3M011. Figure 9
exhibits a protein regulatory network built from this list of
genes using the shortest path algorithm, and shows the
interactions between the ubiquitin pathway leading to
proteasome-dependent protein degradation and the pro-
tein ISGylation pathway. Shown in the interaction net-
work are enzymes common to the ubiquitin and the
ISGylation pathways UBCH8, HERC5 (ceb1) and EFP and
a few of the numerous proteins that are ubiquitinated for
protein degradation and those that are ISGylated. Notable
proteins marked for degradation by ubiquitination are
those relevant to the immune system such as IRF3, IRF8,
STAT1, and STAT5. [83-86] Among the proteins known to
be ISGylated are the ubiquitin enzymes UBCH8 and
HERC5 [79,76], the anti-viral interferon-inducible genes
PKR (EIF2AK2), MX1, and RIG1 [87], signaling proteins
in the JAK-STAT pathway including JAK1, ERK1 and
STAT1 [74,88] and IRF3 [89], which plays a major role in
the innate anti-viral response. Evidence for cross regula-
tion of the ubiquitin and ISGylation pathways has been
reported. ISG15 has been shown to inhibit the ubiquitin/
26S proteasome pathway [90,76], thus inhibiting the deg-
radation of proteins such as IRF3 [89]. ISGylation of the
ubiquitin E2 enzyme UBC13 (UBE2N) has also been
shown to disrupt modification of this enzyme by ubiqui-
tin [87].
ISG15 as well as several of the genes which are known to
be ISGylated including UBCH8, HERC5 and USP18, and
the innate anti-viral response genes RIG1, MX1, PKR, and
IRF3 are also known to be inducible by type 1 interferons
and viruses [66,79,90,91]. Experiments in ISG15 knock-
out mice have shown that IFN-induced antiviral responses
of ISG15-/- mice to vesicular stomatitis and lymphocytic
choriomeningitis virus were not significantly altered [92].
In contrast, similar experiments show increased suscepti-
bility towards influenza virus, herpes virus type 1 (HSV-
1), and Sindbis viruses [66]. The difference in the antiviral
activity of ISG15 towards the different viruses is not clear.
It is postulated that the antiviral effectiveness ISG15 may
depend on the effectiveness of mechanisms the particular
virus may have evolved to counteract it. For example,
influenza B virus produces a viral protein, NS1b which is
capable of binding to ISG15 to prevent protein ISGylation
Protein regulatory network indicates importance of ISGylation pathway in TLR7-mediated activation of pDC Figure 9
Protein regulatory network indicates importance of ISGylation pathway in TLR7-mediated activation of pDC. 
Protein-interaction network was generated for expression changes in pDC stimulated with 3M-852A and 3M-011 4 hr post-
stimulation. The network was generated from a group of genes with the GO ontology classification of ubiquitin cycle using the 
shortest path algorithm. The network summarizes interactions between the ubiquitin and the ISG15 pathways for protein 
modification and the genes that are altered in expression upon stimulation of pDC with TLR7 agonists. Remaining network 
details are as described in Figure 6.BMC Immunology 2007, 8:26 http://www.biomedcentral.com/1471-2172/8/26
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[93]. Similar mechanisms in vesicular stomatitis and lym-
phocytic choriomeningitis virus may function to strongly
counteract the antiviral effects of ISG15 as seen the work
of Osiak et al [92]. The increased expression of enzymes
important for ISGylation as well as innate antiviral genes
that are targets of ISGylation thus underscores the impor-
tance of protein ISGylation in the innate, anti-viral
response of pDC stimulated with TLR7 agonists.
Change in expression of chemokines and chemokine 
receptors
The gene expression analysis in this study shows that acti-
vation of pDC results in increased expression of a large
number of other cytokines and chemokines in addition to
type 1 interferons (see Additional File 1). Figure 6 shows
a protein interaction network for several CC and CXC
chemokines induced by TLR7 agonists in pDC. The high-
est induced chemokines are ligands for CXCR3 with
expression changes ranging from 20-fold to 120-fold. The
CXCR3 ligands include CCL5 (Rantes) which is chemo-
tactic for Memory T cells and monocytes, CXCL11, (ITAC)
and CXCL9 (MIG) which are chemotactic for activated T
cells, and the pleotrophic chemokine CXCL10 (IP10)
which stimulates monocytes, natural killer (NK) cells and
T cells, and modulates their migration [47]. In addition to
CXCR3, CCL5 also activates the chemokine receptors
CCR1, CCR3, CCR4, and CCR5. The ligands for the chem-
okine receptors CXCR1 (IL8RA) and CXCR2 (IL8RB); IL8,
CXCL1 (GRO1), CXCL2 (GRO-beta), and CXCL3 (GRO-
gamma) are chemotactic for a number of cell types includ-
ing T cells, B cells, monocytes, macrophages, neutrophils
and mast cells [47]. These chemokines are induced to a
lower degree (2- to 12-fold change in expression) than the
CXCR3 ligands CXCL9, CXCL10 and CXCL11. Thus, the
data suggest that TLR7-activated pDC predominantly
influence migration of activated T cells.
Only two chemokine receptors are altered in expression
upon activation of pDC by TLR7 agonists; CXCR4 which
is deceased in expression and CCR7, which is increased in
expression. CXCR4 is the receptor for CXCL12 (SDF1,
stromal cell-derived factor which is expressed by HEV
(endothelial venules), bone marrow stromal cells and
tumor stromal cells [94,95]. In contrast, the ligands for
CCR7; CCL19 and CCL21 are expressed by HEV as well as
stromal cells within T cell-rich areas [96]. In addition,
increased expression of CCR7 on dendritic cells is critical
for migration to lymph nodes [97,98]. Thus, the increased
expression of CCR7 with the concomitant decrease in
expression of CXCR4 more specifically predisposes TLR7
activated pDC to migrate to lymph nodes. It is interesting
to note that CXCR4 is one of the receptors for entrance of
HIV-1 into pDC [99]. The reduced expression of CXCR4
may thus have a dual role, in pDC migration and as an
anti-viral mechanism.
Activation of pDC for antigen processing and presentation 
and T-cell co-stimulation
Activation of pDC by TLR7 agonists alters the expression
of various genes involved in antigen processing and pres-
entation (see Additional File 1). TAP1 and TAP2, antigen
peptide transporter 1 and 2 were moderately increased in
expression. Genes involved in antigen presentation were
also increased in expression, including a low and donor
dependent increase in HLADQA1 (MHCII molecule) and
a stronger increase in LAMP3 (DCLAMP). Various genes
involved in T cell costimulation were also increased in
expression including CD80, CD83, CD86 and CD40. In
addition, TNFRSF9 (CD137, 4-1BB) and its ligand
TNFSF9 (4-1BB-L) were increased in expression. TNFSF9
expressed on dendritic cells is known to interact with
TNFRSF9 on activated T cells resulting in Th1 polarization
and, T, and NK cell survival and expansion [100,101]. It is
interesting that both the receptor and ligand-pair are
increased in expression upon stimulation of pDC with
TLR7 agonists, suggesting a role for this pair of molecules
in pDC signal transduction. Thus, as early as 4 hr post-
stimulation with TLR7 agonists, pDC are primed for anti-
gen processing and presentation as well as co-stimulation
of cells of the adaptive immune system.
Activation of pDC through TLR7 leads to increased 
expression of genes in innate anti-viral pathways which 
respond to RNA viruses
Regulation of expression of type 1 interferons through
TLR7 is believed to involve IRF7 and the adaptor molecule
MyD88 [102,36]. In this study we show that stimulation
of pDC with TLR7 agonists results in increased expression
of genes known to be involved in TLR7-signaling and/or
in signaling through other TLRs. The TLR7 adaptor mole-
cule MyD88, TAB2 (TAK1-binding protein 2) and NFκB
[103] are increased in expression. In addition, genes that
interact with TRAF6, the central mediator of signaling
through several TLRs; such as MAP3K8 (TPL2), and
TNFAIP3 (zinc finger protein A20) were also increased in
expression. MAP3K8 has been shown to interact with
TRAF6, IKK-alpha and NFκB [104] and is required for
TLR-mediated ERK activation and induction of pro-
inflammatory cytokines [105]. TNFAIP3 is now recog-
nized as a negative regulator of TLR signaling [106] as well
as signaling through the cytosolic anti-viral pathway
mediated by RIG1 [107]. RIPK2 (receptor interacting pro-
tein kinase 2) which activates IKK-alpha (inhibitor of
nuclear kappa-B kinase alpha) resulting in IRF7-mediated
induction of IFNA [108] and NFκB-mediated induction of
chemokines [109] was also increased in expression. Thus,
activation of TLR7 by TLR7 agonists results in increased
expression of signaling components of TLR7 as well as
other TLRs, thus potentially amplifying TLR signaling
pathways. While some genes are positive drivers of the sig-BMC Immunology 2007, 8:26 http://www.biomedcentral.com/1471-2172/8/26
Page 13 of 19
(page number not for citation purposes)
naling pathways others are negative regulators of the path-
ways, indicating tight regulation of these signals.
In addition to known components of TLR7 signaling,
genes in the signaling pathways for TLR3 and the cytosolic
innate anti-viral pathway mediated by the RNA helicases
MDA5 (IFIH1, interferon-induced helicase C domain con-
taining protein 1) and RIG1 (Retinoic acid inducible gene
1) are over-expressed. Also over-expressed are MDA5 and
LGP2 (a likely ortholog of mouse D11lgp2), gene that is
known to be a negative regulator of the RIG1 pathway
[110]. PKR, a double stranded RNA activated protein
kinase, is also increased in expression. In the TLR3-signal-
ing pathway, TICAM1, the adaptor molecule for TLR3-
[111] is increased in expression. These four pathways
share a common characteristic in that the natural agonists
of these pathways are RNA-based, single stranded RNA
(ssRNA) for TLR7 [11]; double stranded RNA (dsRNA) for
TLR3 [112], PKR [113] and MDA5; and ssRNA and dsRNA
for RIG1 [114]. Thus, the data indicate that signaling
through TLR7 may potentially prime and amplify signal-
ing through TLR3, PKR, and the cytosolic antiviral path-
way. The net effect of this may be an optimization of the
anti-viral response against RNA viruses. This conclusion is
consistent with the synergy between various TLRs includ-
ing TLR7 and TLR3 observed for the induction of
cytokines and cytotoxic T cell responses [115,116].
Conclusion
In this study, we have made the first comprehensive glo-
bal gene expression analysis of high purity pDC stimu-
lated with TLR7 agonists. Even though the induction of
type 1 interferons by TLR7 agonists in pDC has been well
documented, we show the first evidence that a variety of
IFNA subtypes as well as IFNB genes are induced. Given
the evidence that IFNA subtypes differ in potency in their
anti-viral and anti-tumor activities, the induction of a vari-
ety of IFNA subtypes and IFNB by TLR7 agonists may be
an advantage over therapies that utilize a single IFNA sub-
type. In addition to increased expression of type 1 interfer-
ons, which can prime other immune and non-immune
cells for anti-viral response, pDC produce a large number
of chemokines and cytokines which can recruit and mod-
ulate the activity of a variety of cells of the innate and
adaptive immune systems. The data also provides evi-
dence for autocrine transcriptional regulation which
results in increased expression of a large number of inter-
feron-inducible genes with known anti-viral activity, thus
indicating a strong antiviral role of this cell type. Potential
autocrine regulation by chemokines is also implicated in
the large number of genes regulated by other transcription
factors such as CREB1. In addition, the increased expres-
sion of the interferon-inducible gene ISG15, and several
enzymes responsible for ISGlyation as well as genes know
to be ISGylated, underscores the importance of the
ISGylation pathway in activated pDC. The exact role(s)
protein ISGylation plays in activated pDC is not clear. The
fact that several substrates of ISG15 which are also known
to have anti-viral activity are increased in expression sug-
gests a potential role for protein ISGylation in the anti-
viral activity of pDC. Even as early as 4 hr post stimula-
tion, the gene expression data provides evidence for
increased capacity for antigen processing and presentation
and T cell co-stimulatory capacity. A distinct anti-apop-
totic gene expression finger print also shows that stimula-
tion with TLR7 agonists programs pDC for increased cell
survival.
Finally, the data demonstrate the capacity for TLR7-medi-
ated amplification of the innate immune response in
pDC. Stimulation of the TLR7 pathway results in
increased expression of components of TLR7-signaling. In
addition, signaling components of three other innate anti-
viral pathways which respond to RNA viruses, TLR3, PKR
and the cytosolic RIG1/MDA5 pathway are also increased
in expression suggesting priming to maximize anti-viral
response towards RNA viruses. While the data demon-
strates the capacity of the innate immune response to
amplify itself, increased expression of negative regulators
of the three pathways indicates a tight regulation so as to
prevent uncontrolled inflammation.
In summary, the gene expression analysis in this study
provides valuable insight into the molecular pathways
and processes altered in pDC upon stimulation with TLR7
agonists. The study also underscores the powerful
immune stimulatory capacity of synthetic TLR7 agonists
and their potential and demonstrated use in anti-viral and
anti-tumor therapies. 3M-852A is currently in phase II
clinical study for cancer therapy.
Methods
TLR Agonists
Small molecule synthetic TLR7 agonist (3M-852A, N- [4-
(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl-
]methanesulfonamide; formula, C17H23N5O2S; m.w.,
361; and TLR7/8 agonist 3M-011, N-{2- [4-amino-2-
(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-
imethylethyl}methanesulfonamide; formula,
C18H25N5O3S, m.w., 391.5 were prepared by 3M Pharma-
ceuticals. Compounds were dissolved in dimethyl sulfox-
ide (DMSO, Sigma-Aldrich, St Louis, MO, USA) at a
concentration of 10 mM for use in stimulation of cells.
Preparation of Plasmacytoid Dendritic Cells (pDC)
Human peripheral blood mononuclear cells (PBMC)
were obtained from healthy volunteers using an aphaer-
esis procedure at the Memorial Blood Center, Minneapo-
lis MN. Subjects provided informed consent under an
institutional review board prior to blood donation. PBMCBMC Immunology 2007, 8:26 http://www.biomedcentral.com/1471-2172/8/26
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were prepared by Ficoll gradient (Ficoll Paque™, Amer-
sham Bioscience, Uppsala Sweden) as described previ-
ously [14]. Purification of pDC was done by positive
selection using Miltenyi BDCA4+ Cell selection Kits,
(Miltenyi Biotec, Auburn, CA), according to manufac-
turer's recommendations. BDCA-4 magnetic beads kit rea-
gents were added at the recommended ratios, and
incubated for 15 minutes at 10°C. Labeled cells were
washed, and then passed through a D type column in a
SuperMAX magnet. After extensive washing, enriched cells
were centrifuged and labeled for flow sorting using, allo-
phycocyanin (APC) labeled anti-CD123, FITC-labeled
anti-BDCA2 antibodies (Miltenyi Biotec, Auburn, CA),
and phycoerythrene (PE) labeled anti-CD11c, (Becton
Dickinson Biosciences, Franklin Lakes, NJ). Cells were
labeled for 20 minutes at 20°C, washed in 15 volumes of
Hank's Balanced Salt Solution (HBSS), 25mM HEPES
(Biosource, state, country), 2% Human Serum (Cambrex
Bio Science, Walkersville MD). Flow sorting was per-
formed on a FACSAria™ flow cytometer (Becton Dickin-
son Co., Franklin Lakes, NJ). Cells were collected into
Iscove's Modified Dulbecco's Medium (IMDM), with 10%
human serum (Cambrex Bio Science, East Rutherford,
New Jersey) and allowed to rest for two hours prior to
stimulation. Flow purified cells used for stimulation with
TLR agonists were 99% or greater in purity as determined
by the percentage of CD123+/BDCA2+/CD11c- cells.
pDC were stimulated with 5 µM each of 3M-852A or 3M-
011 dissolved in DMSO or the same volume of DMSO.
The final concentration of DMSO was 0.1%. After four
hours of stimulation, cells were harvested by centrifuga-
tion and RNA extracted as outlined below. 3M-852A and
3M-011 were evaluated in pDC obtained from the same
two donors. In addition, 3M-852A was evaluated in pDC
from two other donors.
Analysis of Secreted Cytokines and Chemokines
Cell culture supernatants collected 4 hr after stimulation
of pDC were frozen and later evaluated for TNFα, IFNα,
and IL-12 protein. Human IFNα was measured by ELISA,
(PBL Biomedical Laboratories, Piscataway, NJ). TNFα and
IL-12 were measured by ORIGEN (IGEN) assay (BioVeris
Corp, Gaithersburg, MD) [14]. In addition, supernatants
from two experiments were evaluated using a Human
Cytokine 25-Plex Luminex™ kit (Biosource, Camarillo,
CA). Cytokines assayed were; IL-1β, IL-1ra, IL-2, IL-2R, IL-
4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40/p70, IL-13, IL-15,
IL-17, TNFα, IFNα, IFNγ, GM-CSF, MIP-1α, MIP-1β, IP-
10, MIG, Eotaxin, RANTES, and MCP-1.
RNA extraction and Reverse Transcription
RNA was extracted from cell pellets using the Qiagen RNe-
asy kit (Qiagen Inc., Valencia CA), according to manufac-
turer's recommendations. Purified RNA was reverse
transcribed using SuperScript Double Stranded cDNA
Synthesis kit (Invitrogen Corp, Gaithersburg MA) using a
GeneChip® T7-Oligo(dT) Promoter Primer Kit (Affymetrix
Inc. Santa Clara CA) according to manufacturer's recom-
mendations.
Quantitative Polymerase Chain Reaction
Real time Reverse Transcriptase Polymerase Chain Reac-
tion (RT-PCR) was performed using custom TaqMan® Low
Density Arrays (Applied Biosystems, Foster City, CA).
Each Low Density Array contained TaqMan® reagents for
23 different genes and GAPDH. Primers and probes for
IFN subtypes IFNA2, IFNA8, IFNA1/13, IFNA14, IFNA21,
and IFNB1 were purchased as pre-developed reagents
from Applied Biosystems. Primers and probes for IFN sub-
types IFNA5, IFNA7 and IFNA10 were designed in house
using Primer Express Software (Applied Biosystems, Fos-
ter City CA) and custom made by Applied Biosystems. The
following primer/probe sets were used: IFNA5; forward
primer -TGTGATCTGCCTCAGACC-, reverse primer-GAT-
TCTTCCCATTTGTGCCATTA-, TaqMan probe AACAGGA
GGACTTTGATG; IFNA7, forward primer -GGTAGCCTAG
TGATATTTG-, reverse primer -GATGGATTTGTAGCTGAG
T-, TaqMan probe -CCTTTTCTTTACTGATG-; IFNA10, for-
ward primer -GTTATCCATCTCAAGTAGCCT-, reverse
primer -GATTTGTAGCTGAGCACCA-, TaqMan probe -
TCTTTACTTATGGCCGTG-. TaqMan®  probes were FAM
and MGB labeled. PCR was performed for thirty-five
cycles of 30sec at 95°C and 1 min at 60°C, preceded by a
2 min at 50°C and 10 min. incubation at 95°C, using an
ABI PRIZM 7900HT Sequence Detection System (Applied
Biosystems, Foster City CA) and analyzed according to
manufacturer's instructions. Relative quantitation of gene
expression was performed according to the ∆∆Ct method
using GAPDH for normalization (User Bulletin #2, PE
Applied Systems 1]. Fold change in expression due to
stimulation with TLR agonists was calculated relative to
vehicle- stimulated samples.
Affymetrix GeneChip Analysis
Samples for Affymetrix GeneChip analysis were prepared
by one round of amplification according to manufac-
turer's instructions. The cDNAs were amplified and biotin
labeled using GeneChip® Expression 3'-Amplification Rea-
gents for IVT Labeling (Affymetrix Inc. Santa Clara, CA).
Hybridization onto Affymetrix U133A Human Gene-
Chip® Arrays (Affymetrix Inc, Santa Clara, CA) washing
and image acquisition was performed according to the
manufacturer's recommendations. Image analysis was
performed using Gene Chip Operating Software (GCOS).
(Affymetrix Inc. Santa Clara, CA). The quality of the
images was ascertained by monitoring the noise, back-
ground, percent transcript present, and the 3'/5' ratio for
the housekeeping gene glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH). 3'/5' ratios for GAPDH were 0.9 ±
0.2 and were within acceptable value of 1. GeneChipsBMC Immunology 2007, 8:26 http://www.biomedcentral.com/1471-2172/8/26
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from each donor were normalized to their respective vehi-
cle control chips for determination of fold change in
expression. The data were imported into Data Mining
Tools, (DMT) and filtered based on a signal detection p-
value < 0.01, and signal log ratio (log 2 fold change) < -
1.5 or > 1.5. Probes for which one or more of the samples
passed these criteria were brought into Microsoft® Excel
where the list was further filtered. Probes that did not
show consistent signal detection p-value (less than 0.01)
and an expression change p-value (less than 0.005) across
replicates for each TLR agonist was eliminated. Redundant
Affymetrix probes were manually removed from the data
leaving 680 unique genes that showed consistent change
across replicates for at least one of the TLR agonists.
Cluster analysis of the 680 genes was performed with
Spotfire DecisionSite-8.1 for Functional Genomics (Spot-
fire Inc, Somerville, MA), using the Unweighted Pair-
Group Method with Arithmetic mean (UPGMA) and the
Euclidean similarity measure. Several tools were used to
understand the gene functions and the biological proc-
esses represented in the data. Gene Ontology classifica-
tion was made using the Ontology Browser in Spotfire
Decisions Site for Genomcis, as well as the network inter-
actions software MetaCore (described below). Gene
Ontology files were downloaded from the gene ontology
website [117] for use in Spotfire. The ontology browser
calculates a Fisher's Exact Test p-value, which reflects the
chance that the gene ontology category is represented by
random chance [118]. P-value < 0.05 is considered signif-
icant.
Functional analysis of expression data
Gene regulatory networks were generated using MetaCore
analytical suite version 4.2 build 8168 (GeneGo, St
Joseph, MI). MetaCore is a web-based suite for functional
analysis of experimental data in the context of manually
curated human protein interactions, canonical pathways,
and knowledge base ontologies of cellular processes, dis-
eases, and toxicology. The database includes over 160,000
human protein interactions and metabolic reactions, as
well as known drugs, metabolites, nutrients and other
bioactive compounds. The experimental data in MetaCore
can be subjected to enrichment analysis [119] in 6 func-
tional ontologies including GeneOntology processes
(GO), GeneGo process networks, Diseases, GeneGo Dis-
eases, Canonical pathway maps and Metabolic processes.
Enrichment analysis in GO processes was used in this
study. Both enrichment analysis and calculation of statis-
tical significance of networks are based on p-values which
are defined as the probability of a given number of genes
from the input list to match a certain number of genes in
the ontology's folder, or the probability of the network's
assembly from a random set of nodes (genes) the same
size as the input list (described in the supplimentary files
in [120] . The whole data set of 680 genes was used to
build networks using the Analyze networks (transcription
regulation) algorithm and Analyze networks (receptor)
networks algorithm which generate sub-networks cen-
tered on transcription factors and receptors respectively.
The sub-networks were scored and prioritized based on
relative enrichment with the data from input list and sat-
uration with "canonicl pathways" using p-values and z-
scores as statistical metrics [120]. Networks of interest
thus obtained were further built by merging different net-
works and or expanding interactions around a given
object (protein/gene). Some networks were built using the
shortest path (SP) algorithm (directed graph) using
selected smaller data sets of 3 to 40 genes.
Abbreviations
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